Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can popular Weight-Loss drugs quiet the urge to eat for comfort?

NCT ID NCT07803185

Knowledge-focused Sponsor: TC Erciyes University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 03, 2026 · Last updated Sep 04, 2026 · Updated 1 time

Summary

Researchers are following 60 adults who are starting GLP-1 receptor agonist therapy for weight loss. They will measure changes in anhedonia, the loss of pleasure in activities, and emotional eating behaviors at the start of treatment and again after 6 months. The study uses questionnaires to track these changes, aiming to understand how these drugs might influence mood and eating habits beyond just reducing appetite.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
GLP-1 receptor agonist therapy (a class of weight-loss drugs)
What this could lead to
If this study finds links, it could guide how doctors monitor mood and eating habits in people taking GLP-1 drugs for weight loss.
What could go wrong
This is an observational study with only 60 participants, so it cannot prove cause and effect. Results may not apply to everyone, and the follow-up is limited to 6 months.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2026

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult patients attending the Erciyes University Faculty of Medicine Endocrinology and Metabolism Outpatient Clinic who are newly prescribed GLP-1 receptor agonists for weight management.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18 years or older * Newly initiated on GLP-1 receptor agonist treatment for weight reduction * Willingness to participate in evaluations at baseline and at the 6-month follow-up * Ability to read and understand Turkish and possess the cognitive capacity to answer questionnaire items * Voluntary provision of written informed consent Exclusion Criteria: * Use of GLP-1 receptor agonists for indications other than weight loss * Cognitive, neurological, or severe psychiatric conditions preventing completion of self-report questionnaires * Substantial missing, inconsistent, or unverifiable questionnaire data compromising analysis integrity * Non-participation or dropout at the 6-month follow-up evaluation

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Anhedonia are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Anhedonia Emotional Eating Obesity obesity disorder Weight Loss

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Anhedonia Emotional eating Obesity

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Erciyes University Medical Faculty Hospitals, Department of Endocrinology and Metabolism

    RECRUITING

    Kayseri, Melikgazi, 38000, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.